Hydrogel Peptidic Ligand System for Sustained Antibody Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current protein-based therapeutics, such as antibodies, often require repetitive dosing due to short therapeutic duration, leading to invasive administration methods and potential infections, while existing sustained release strategies face challenges like protein denaturation and strong affinity interactions that hinder controlled release.
Innovation Solution
A protein-release system utilizing a hydrogel with peptidic ligands covalently coupled to a polymeric network that selectively bind to the Fragment Crystallizable (Fc) domain of antibodies, allowing for tunable and sustained release through affinity interactions with a dissociation constant between 10^-4 to 10^-10 M, enabling the use of unmodified antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If affinity interactions with strong binding affinity are used to immobilize antibodies, then the antibody is not sufficiently released, but if weak affinity interactions are used, then controlled release cannot be achieved
Solution Approach 1:
The patent applies parameter changes by systematically varying the dissociation constant (KD) of the affinity ligand-antibody interaction to achieve optimal release control. Specifically, the patent identifies that ligands with KD values in the range of 10^-6 to 10^-10 M provide sustained release, while weaker ligands (KD > 10^-6 M) result in insufficient binding, and stronger ligands (KD < 10^-10 M) prevent release. This quantitative parameter optimization resolves the contradiction between reliable immobilization and controlled release.
2Duration of action of moving object
If protein encapsulation is used for sustained release, then therapeutic concentrations can be maintained, but protein denaturation and minimal loading occur
Solution Approach 1:
The patent applies the extraction principle by removing the problematic encapsulation step entirely. Instead of enclosing proteins within hydrogel matrices (which causes denaturation and loading issues), the patent extracts the protein delivery function and implements it through surface-bound affinity ligands that selectively bind and release intact proteins. This approach maintains protein bioactivity while achieving sustained release through controlled affinity interactions.
Solution Approach 2:
The patent uses affinity ligands as intermediary molecules that mediate between the hydrogel matrix and the antibody. These ligands are covalently attached to the hydrogel and provide reversible, specific binding to antibodies through non-covalent interactions. This intermediary approach allows the hydrogel to serve as a delivery vehicle without direct contact between the matrix and the protein therapeutic, preventing denaturation while enabling controlled release.
3Duration of action of moving object
If repetitive dosing is used to achieve long-term therapeutic benefit, then therapeutic concentrations are maintained, but invasive administration and infection risk increase
Solution Approach 1:
The patent implements continuity of useful action by designing a sustained release system that maintains therapeutic antibody concentrations over extended periods (weeks to months) through controlled affinity-based release. The hydrogel-antibody complex provides continuous delivery of the therapeutic agent, eliminating the need for repetitive injections and thereby reducing infection risk and improving patient compliance while maintaining effective therapeutic levels.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables controlled and sustained release of antibodies without protein modification, maintaining therapeutic concentrations for extended periods with fewer injections, enhancing patient compliance and treatment effectiveness while preserving protein bioactivity.
Implementation Method 1
The peptidic ligands are selected to reversibly bind, by affinity, to the fragment crystallizable (Fc) constant region of the antibody
Data Source
AI summary
The present disclosure provides a protein-release system for sustained release of proteins. The system includes a hydrogel comprising a polymeric network, proteins having a portion corresponding to a portion of a fragment crystallization (Fc) constant region of an antibody, and peptidic ligands covalently coupled to the polymeric network, the peptidic ligands comprising an amino acid sequence having a binding affinity to the portion of the Fc constant region, each protein being reversibly bound by affinity to the peptidic ligands.